多西紫杉醇联合奥沙利铂治疗晚期非小细胞肺癌32例临床观察

The clinical study of Taxotere plus Oxaliplatin in the second line therapy of advanced NSCLC

目的观察多西紫杉醇联合奥沙利铂二线治疗晚期非小细胞肺癌（NSCLC）的疗效和毒性。方法采用多西紫杉醇联合奥沙利铂治疗32例一线治疗失败的晚期NSCLC3个周期后，根据RECIST标准，评价疗效，不良反应按NCI—CTC3．0标准评价。结果无CR病例，PR9例，SD16例，PD7例，有效率（CR＋PR）28．13％，常见不良反应是白细胞减少、恶心、呕吐、肝功能损害、神经毒性和血小板减少等，并均为轻、中度，经对症处理后缓解和恢复，未出现严重不良反应。结论采用多西紫杉醇联合奥沙利铂治疗一线治疗失败的晚期NSCLC较安全有效。

Objective To observe the efficacy and drug-related toxicity of taxotere plus oxalipatin in the second line treatment of advanced non-smaU cell lung cancer （NSCLC）. Methods 32 non-small cell lung cancer patients, which progressed after first line therapy, were treated with taxotere plus oxalipatin 3 cycles, then evaluate the effect according to RECIST standard and judge the adverse effect with NCI-CTC3.0 standard. Results CR 0 case, PR 9 cases, SD 16 cases, PD 7 cases, total effective rate （CR＋PR） is 28.13%, main toxicity and adverse reaction is aleucocytosis, nausea and vomitting, hepatic disfunction, neurotoxicity, thrombocytopenia and so on, most of them is slight and midrange, and can be relieved and recovered after treatment, no fatal toxicity and adverse reaction were observed. Conclusions Using taxotere plus oxalipatin in the second line treatment of advanced non-small cell lung cancer （NSCLC） is efficient and safe.